NEJM· @NEJM · X·· 9 天前精选AI 评分67
AI 导读
在#TLM26会议上公布的试验结果显示,靶向肝脏表达CIDE B的siRNA单次给药后,代谢功能障碍相关脂肪性肝病(MASLD)患者在第36周肝脏脂肪减少58%至80%。完整试验结果已由NEJM发布。
推荐理由
单次给药后36周肝脏脂肪降低58%至80%,为MASLD的siRNA干预提供了可对照的早期人体数据。
正文
Presented at #TLM26:
A single dose of an siRNA targeting liver expression of 𝘊𝘐𝘋𝘌𝘉 was associated with a reduction in liver fat of 58 to 80% at week 36 after treatment in persons with metabolic dysfunction–associated steatotic liver disease. Full trial results: https://nej.md/4fcxkjE
@AASLDtweets
来源:NEJM · x.com